Joanna Szkandera1, Martin Pichler2, Gudrun Absenger1, Michael Stotz2, Franziska Arminger2, Melanie Weissmueller2, Renate Schaberl-Moser2, Hellmut Samonigg2, Peter Kornprat3, Tatjana Stojakovic4, Alexander Avian5, Armin Gerger6. 1. Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria; Research Unit: Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. 2. Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. 3. Division of General Surgery, Department of Surgery, Medical University of Graz, Graz, Austria. 4. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. 5. Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria. 6. Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria; Research Unit: Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. Electronic address: armin.gerger@medunigraz.at.
Abstract
BACKGROUND: Recent evidence indicates that tumor progression involves factors of systemic inflammation, such as platelets and lymphocytes. In this study, we investigated the prognostic relevance of the preoperative platelet to lymphocyte (P/L) ratio on time to recurrence (TTR) and overall survival (OS) in patients with stage II and III colon cancer (CC) who underwent curative resection. METHODS: In this retrospective study, 372 CC patients were included. Kaplan-Meier curves and multivariate Cox proportional models were calculated for TTR and OS. RESULTS: In univariate analysis, the elevated P/L ratio was significantly associated with decreased TTR (HR = 1.60, 95% CI = 1.02 to 2.51, P = .040) and remained significant in multivariate analysis (HR = 1.65, 95% CI = 1.05 to 2.58, P = .030), where HR and CI represent Hazard ratio and confidence interval, respectively. Patients with elevated P/L ratio showed a median TTR of 116 months. In contrast, patients with low P/L ratio had a median TTR of 132 months. In OS analysis, the elevated P/L ratio showed a trend toward decreased OS in univariate analysis (HR = 1.54, 95% CI = .95 to 2.48, P = .079). CONCLUSION: In this study, we identified the preoperative P/L ratio as a prognostic marker for TTR in stage II and III CC patients.
BACKGROUND: Recent evidence indicates that tumor progression involves factors of systemic inflammation, such as platelets and lymphocytes. In this study, we investigated the prognostic relevance of the preoperative platelet to lymphocyte (P/L) ratio on time to recurrence (TTR) and overall survival (OS) in patients with stage II and III colon cancer (CC) who underwent curative resection. METHODS: In this retrospective study, 372 CC patients were included. Kaplan-Meier curves and multivariate Cox proportional models were calculated for TTR and OS. RESULTS: In univariate analysis, the elevated P/L ratio was significantly associated with decreased TTR (HR = 1.60, 95% CI = 1.02 to 2.51, P = .040) and remained significant in multivariate analysis (HR = 1.65, 95% CI = 1.05 to 2.58, P = .030), where HR and CI represent Hazard ratio and confidence interval, respectively. Patients with elevated P/L ratio showed a median TTR of 116 months. In contrast, patients with low P/L ratio had a median TTR of 132 months. In OS analysis, the elevated P/L ratio showed a trend toward decreased OS in univariate analysis (HR = 1.54, 95% CI = .95 to 2.48, P = .079). CONCLUSION: In this study, we identified the preoperative P/L ratio as a prognostic marker for TTR in stage II and III CC patients.
Authors: Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan Journal: Med Oncol Date: 2014-09-14 Impact factor: 3.064
Authors: Martin Bailon-Cuadrado; Ekta Choolani-Bhojwani; Francisco J Tejero-Pintor; Javier Sanchez-Gonzalez; Mario Rodriguez-Lopez; Baltasar Perez-Saborido; Jose L Marcos-Rodriguez Journal: Updates Surg Date: 2017-12-08
Authors: Marco Puzzoni; Nicola Silvestris; Francesco Leone; Riccardo Giampieri; Luca Faloppi; Laura Demurtas; Emanuela Dell'Aquila; Donatella Marino; Oronzo Brunetti; Silvio Ken Garattini; Elena Ongaro; Giorgio Astara; Laura Orgiano; Giuseppe Aprile; Daniele Santini; Mario Scartozzi Journal: Target Oncol Date: 2016-10 Impact factor: 4.493